Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Operating Expenses (2020 - 2025)

Caribou Biosciences has reported Operating Expenses over the past 6 years, most recently at $32.4 million for Q4 2025.

  • Quarterly Operating Expenses fell 20.9% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.5 million through Dec 2025, down 9.69% year-over-year, with the annual reading at $159.5 million for FY2025, 9.69% down from the prior year.
  • Operating Expenses was $32.4 million for Q4 2025 at Caribou Biosciences, up from $31.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $50.2 million in Q2 2025 and troughed at $14.8 million in Q1 2021.
  • The 5-year median for Operating Expenses is $34.4 million (2022), against an average of $34.2 million.
  • Year-over-year, Operating Expenses surged 139.66% in 2021 and then dropped 21.52% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $23.0 million in 2021, then skyrocketed by 49.23% to $34.3 million in 2022, then rose by 19.64% to $41.0 million in 2023, then dropped by 0.12% to $41.0 million in 2024, then fell by 20.9% to $32.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Operating Expenses are $32.4 million (Q4 2025), $31.6 million (Q3 2025), and $50.2 million (Q2 2025).